Starmab Secures Tens of Millions in RMB in Series A+ Financing to Advance Innovative Multispecific Antibody Drug Development

Investment Circle (ID: pedaily2012) February 28th news, Beijing StarMab BioMed Technology Ltd. (Abbreviation: StarMab BioMed) announced the completion ofTens of Millions of RMB in A+ Round Financing. This round of financing was led byZhuhai Science and Technology Investment, Zhuhai High-Tech Financial Investment, and Grand Alliance United Investment, Qidian Capital served as the financial advisor for subsequent rounds of financing.

Before this round of financing, StarMab BioMed had already gained favor from well-known institutions in China such as Aethan Capital, CICC Capital, Cowin Capital, and Chang'an Private Capital.

StarMab BioMed, established in 2019 and located in Beijing Zhongguancun Life Science Park, is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs. Based on its proprietary VHH multi-antibody biologic drug platform technology, the company focuses on addressing unmet medical needs by developing First-in-Class and Best-in-Class innovative multifunctional antibody drugs, as well as advancing clinical research and commercialization globally.

Its VHH antibody discovery platform ensures efficient generation and screening of VHH antibodies to obtain VHH antibody candidates with high affinity and high bioactivity. Its proprietary antibody engineering optimization platform effectively addresses issues related to antibody stability, immunogenicity, half-life, and manufacturability. The uniquely structured VHH multi-antibody molecules exhibit high-affinity targeted binding and synergistic effects; adjustable half-life; mediation of ADCC and ADCP; and possess characteristics such as simple structure, small molecular weight, high expression levels, high purification recovery rate, and excellent stability.

Currently, StarMab BioMed has developed a series of novel biologics with independent intellectual property rights. Several First-in-class multifunctional antibody biologics are undergoing early clinical trials in China and the United States. Among them, SM3321 has been granted IND approval in both China and the U.S. and has entered Phase I clinical trials. Preclinical data have shown excellent anti-tumor efficacy and safety. Its unique structural design enables high-affinity targeting and binding to multiple tumor sites while activating immune cell functions, achieving specific killing of tumor cells while minimizing non-specific toxic reactions.

StarMab BioMed's technology in antibody production has also gained wide recognition within the industry. By using traditional CHO antibody production and purification processes, it can achieve industrial-scale production levels.

Recently, StarMab BioMed has obtained the authorization for Lonza's XS® Pichia yeast expression production system, which can greatly simplify the production and purification process of VHH antibodies. While ensuring the bioactivity and yield of the antibodies, it significantly reduces production time and cost.